This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Svoboda J , Bair SM , Landsburg DJ , Nasta SD , Nagle SJ , Barta SK , Khan N , Filicko-O'Hara J , Gaballa S , Strelec L , Chong E , Mitnick S , Waite TS , King C , Ballard H , Youngman M , Gerson J , Plastaras JP , Maity A , Bogusz AM , Hung SS , Nakamura H , Nejati R , Steidl C , Lim M , Ruella M , Schuster SJ
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
Haematologica. 2020 May 15
PMID: 32414850 URL: https://www.ncbi.nlm.nih.gov/pubmed/32414850
AbstractWe conducted a phase I/II multicenter trial using 6 cycles of brentuximab vedotin (BV) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment of patients with CD30-positive (+) B-cell lymphomas. Thirty-one patients were evaluable for toxicity and 29 for efficacy including 22 with primary mediastinal B-cell lymphoma (PMBCL), 5 with diffuse large B-cell lymphoma (DLBCL), and 2 with gray zone lymphoma (GZL). There were no treatment-related deaths; 32% of patients had non-hematological grade 3/4 toxicities. The overall response rate was 100% (95% CI: 88-100) with 86% (95% CI: 68-96) of patients achieving complete response at the end of systemic treatment. Consolidative radiation following end of treatment response assessment was permissible and used in 52% of all patients including 59% of patients with PMBCL. With a median follow-up of 30 months, the 2-year progression-free survival (PFS) and overall survival (OS) were 85% (95% CI: 66-94) and 100%, respectively. In the PMBCL cohort, 2-year PFS was 86% (95% CI: 62-95). In summary, BV-R-CHP with or without consolidative radiation is a feasible and active frontline regimen for CD30+ B-cell lymphomas (NCT01994850).
Notes1592-8721 Svoboda, Jakub Bair, Steven M Landsburg, Daniel J Nasta, Sunita Dwivedy Nagle, Sarah J Barta, Stefan K Khan, Nadia Filicko-O'Hara, Joanne Gaballa, Sameh Strelec, Lauren Chong, Elise Mitnick, Sheryl Waite, Terease S King, Cara Ballard, Hatcher Youngman, Matthew Gerson, James Plastaras, John P Maity, Amit Bogusz, Agata M Hung, Stacy S Nakamura, Hisae Nejati, Reza Steidl, Christian Lim, Megan Ruella, Marco Schuster, Stephen J Journal Article Italy Haematologica. 2020 May 15. pii: haematol.2019.238675. doi: 10.3324/haematol.2019.238675.